Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-RBP2b antibodies
- Development stage
- Preclinical
- Modality
- Antibody-Based Therapeutics
01
Overview
Anti-RBP2b antibodies are monoclonal or polyclonal antibodies that target the Reticulocyte Binding Protein 2b (RBP2b) of *Plasmodium vivax*, a key parasite ligand involved in the invasion of human reticulocytes. RBP2b normally binds to the transferrin receptor 1 (TfR1) on the surface of reticulocytes to facilitate entry. Anti-RBP2b antibodies are studied as potential therapeutic or vaccine-induced agents to block this interaction and prevent malaria infection. Additionally, naturally acquired anti-RBP2b antibodies in endemic populations serve as serological exposure markers (SEMs) to identify individuals with recent *P. vivax* infections.
- Other names
- anti-Plasmodium vivax RBP2b antibodiesanti-PvRBP2b antibodiesanti-PvRBP-2b antibodiesanti-PvRBP 2b antibodiesanti-Reticulocyte Binding Protein 2b antibodies
Beyond the preview
Go deeper on anti-RBP2b antibodies.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-RBP2b antibodies.